Apolipoprotein C-III Inhibition - Killing Two Birds with One Stone?
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 38320505.
- Also identified by DOI 10.1056/EVIDe2300239.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this issue of <i>NEJM Evidence</i>, Gaudet et al.<sup>1</sup> report on safety and efficacy of a strategy targeting apolipoprotein C-III (APOC3) using a silencing ribonucleic acid (RNA; ARO-APOC3). In a phase I trial comprising 52 healthy volunteers (triglycerides [TG], >80 mg/dl), 40 patients with hypertriglyceridemia (TG, >300 mg/dl), and 20 patients with chylomicronemia (TG, >880 mg/dl), ARO-APOC3 or placebo was administered subcutaneously either once or twice, with doses given on days 1 and 29. The primary goal was to examine the safety of ARO-APOC3. Injection site reactions were the most commonly observed adverse clinical event; no adverse effects led to discontinuation of the study drug.
Medical subject headings
- Hypertriglyceridemia